EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Volume 204 / Numéro 1 (2010) Biologie Aujourd'hui, 204 1 (2010) 61-70 References
Free Access
Issue
Biologie Aujourd'hui
Volume 204, Number 1, 2010
Page(s) 61 - 70
Section L'immunothérapie passive aujourd'hui
DOI https://doi.org/10.1051/jbio/2009042
Published online 8 avril 2010
  • Abroug F., Elatrous S., Nouira S., Haguiga H., Touzi N., Bouchoucha S., Serotherapy in scorpion envenomation: a randomised controlled trial. Lancet, 1999, 354, 906-909. [CrossRef] [PubMed] [Google Scholar]
  • Audebert F., Urtizberea M., Sabouraud A., Scherrmann J.M., Bon C., Pharmacokinetics of Vipera aspis venom after experimental envenoming in rabbits. J Pharmacol Exp Ther, 1994, 268, 1512–1517. [PubMed] [Google Scholar]
  • Behring E.A., Kitasato S., Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Deutsch Medizinisch Wochenschrift, 1890, 49, 113-1145. [Google Scholar]
  • Bokata S., Epidémiologie et prise en charge des morsures de serpent dans la province de Bas-Congo (République Démocratique du Congo). Bull Soc Pathol Exot, 2005, 98, 307-309. [PubMed] [Google Scholar]
  • Burnouf T., Griffiths E., Padilla A., Seddik S., Stephano M.A., Gutiérrez J.M., Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals, 2004, 32, 115-28. [CrossRef] [PubMed] [Google Scholar]
  • Calmette A., L'immunisation artificielle des animaux contre le venin des serpents, et la thérapeutique expérimentale des morsures venimeuses. CR Soc Biol, 1894, 46, 120-124. [Google Scholar]
  • Casasola A., Ramos-Cerrillo B., de Roodt A.R., Carbajal Socedo A., Chippaux J.-P., Alagón A., Stock R.P., Paraspecific neutralization of the venom of African species of cobra by an equine antiserum against Naja melanoleuca: a comparative study. Toxicon, 2009, 53, 602-608. [Google Scholar]
  • Chippaux J.-P., Snake-bites: appraisal of the global situation. Bull WHO, 1998a, 76, 515-524. [Google Scholar]
  • Chippaux J.-P., The development and use of immunotherapy in Africa. Toxicon, 1998b, 36, 1503-1506. [CrossRef] [PubMed] [Google Scholar]
  • Chippaux J.-P., The treatment of snake bites: analysis of requirements and assessment of therapeutic efficacy in tropical Africa. A. Ménez A. (Ed.). Perspectives in molecular toxinology, 2002, John Wiley & Sons, Chichester, pp. 457-72. [Google Scholar]
  • Chippaux J.-P., Goyffon M., Producers of antivenomous sera. Toxicon, 1983, 21, 739-752. [CrossRef] [PubMed] [Google Scholar]
  • Chippaux J.-P., Goyffon M., Production and use of snake antivenom. In A.T. Tu (Ed.). Reptiles and Amphibian Venoms, 1991, Dekker Inc., New York, 5, pp. 529-555. [Google Scholar]
  • Chippaux J.-P., Goyffon M., Venoms, antivenoms and immunotherapy, Toxicon, 1998, 36, 823-846. [Google Scholar]
  • Chippaux J.-P., Goyffon M., Availability of the commercial antivenoms. 13th I.S.T. World Congress on Animal, Plant, Microbial Toxins, Paris (France), 18-22 septembre 2000. [Google Scholar]
  • Chippaux J.-P., Goyffon M., Epidemiology of scorpionism: a global appraisal. Acta Tropica 2008, 107, 71-79. [Google Scholar]
  • Chippaux, J.P., Kambewasso A., Morsures de serpent et disponibilité en sérum antivenimeux dans la communauté urbaine de Niamey, Niger. Bull Soc Pathol Exot, 2002, 95, 181-183. [PubMed] [Google Scholar]
  • Chippaux J.-P., Lang J., Amadi Eddine S., Fagot P., Rage V., Le Mener V., Clinical safety and efficacy of a polyvalent F(ab')2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. Trans R Soc Trop Med Hyg, 1998, 92, 657-662. [Google Scholar]
  • Chippaux J.-P., Lang J., Amadi-Eddine S., Fagot P., Le Mener V., Treatment of snake envenomation by a new polyvalent antivenom composed of highly purified F(ab')2: results of a clinical trial in Northern Cameroon. Am J Trop Med Hyg, 1999, 61, 1017-1018. [PubMed] [Google Scholar]
  • Chippaux J.-P., Vieillefosse S., Sall O., Mafouta R., Diallo A., Evaluation de l'incidence des morsures de serpent au Sénégal. Bull Soc Pathol Exot, 2005, 98, 277-282. [PubMed] [Google Scholar]
  • Chippaux J.-P., Massougbodji A., Stock R.P., Alagon A., Clinical trial of a F(ab')2 polyvalent equine antivenom for African snakebites in Benin. Am J Trop Med Hyg 2007, 77, 538-546. [Google Scholar]
  • Chippaux J.-P., Stock R., Massougbodji A., Review: Methodology of clinical studies dealing with the treatment of envenomation. Toxicon, 2009, soumis. [Google Scholar]
  • Diffo J.L.D., Dzikouk G., LeBreton M., Ngoa L.E., Chirio L., Moyou R.S., Distribution des sérums antivenimeux au Cameroun. Bull Soc Pathol Exot, 2005, 98, 302-303. [PubMed] [Google Scholar]
  • Dzikouk G.D., Etoundi Ngoa L.S., Thonnon J., Dongmo A.B., Rakotonirina V.S., Rakotonirina A., Chippaux J.-P. Titrage comparatif de trois sérums antivenimeux d'Afrique sub-saharienne. Bull Soc Pathol Exot, 2002, 95, 144-147. [PubMed] [Google Scholar]
  • Fayomi B., Massougbodji A., Chobli M., Données épidémiologiques sur les cas de morsures de serpent déclarés au Bénin de 1994 à 2000. Bull Soc Pathol Exot, 2002, 95, 178-180. [PubMed] [Google Scholar]
  • Felton L.D., Dissociation of the specific protein precipitate of antipneumococcus horse serum, and a comparison with a protein isolated by chemical means from this immune serum. J Immun, 1932, 22, 453-467. [Google Scholar]
  • Harrison R.A., Hasson S.S., Harmsen M., Laing G.D., Conrath K., Theakston R.D., Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon, 2006, 47, 364-368. [CrossRef] [PubMed] [Google Scholar]
  • Hawgood B.J., Doctor Albert Calmette 1863-1933: founder of antivenomous serotherapy and of antituberculous BCG vaccination. Toxicon, 1999, 37, 1241-1258. [CrossRef] [PubMed] [Google Scholar]
  • Isbister G.K., O'Leary M., Miller M., Brown S.G., Ramasamy S., James R., Schneider J.S., A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. Br J Clin Pharmacol, 2008, 65, 139-143. [CrossRef] [PubMed] [Google Scholar]
  • Kasturiratne A., Wickremasinghe A.R., de Silva N., Gunawardena N.K., Pathmeswaran A., Premaratna R., Savioli L., Lalloo D.G, de Silva H.J., The global burden of snakebite: A literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 2008, 5, e218 [Google Scholar]
  • Krifi M.N., Savin S., Debray M., Bon C., El Ayeb M., Choumet V., Pharmacokinetic studies of scorpion venom before and after antivenom immunotherapy. Toxicon, 2005, 45, 187-198. [CrossRef] [PubMed] [Google Scholar]
  • Nguyen L., Principes de production d'immunoglobulines thérapeutiques hautement purifiées. Biologie Aujourd'hui, 2010, 204, 55-59. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  • Olvera A., Ramos-Cerrillo B., Estévez J., Clement H., de Roodt A., Paniagua-Solís J., North and South American Loxosceles spiders: development of a polyvalent antivenom with recombinant sphingomyelinases D as antigens. Toxicon, 2006, 48, 64-74. [CrossRef] [PubMed] [Google Scholar]
  • Oukkache N., Rosso J.P., Alami M., Ghalim N., Saïle R., Hassar M., Bougis P.E., Martin-Eauclaire M.-F., New analysis of the toxic compounds from the Androctonus mauretanicus mauretanicus scorpion venom. Toxicon, 2008, 51, 835-852. [CrossRef] [PubMed] [Google Scholar]
  • Phisalix C., Bertrand G., Sur la propriété antitoxique du sang des animaux vaccinés contre le venin de vipère. CR Soc Biol, 1894, 46, 111-113. [Google Scholar]
  • Porter R.R., Separation and isolation of fractions of rabbit gamma-globulin containing the antibody and antigenic combining sites. Nature, 1958, 182, 670-671. [CrossRef] [PubMed] [Google Scholar]
  • Ramos-Cerrillo B., de Roodt A.R., Chippaux J.-P., Olguín L., Casasola A., Guzmán G., Paniagua-Solís J., Alagón A., Stock R.P., Characterization of a new polyvalent antivenom (Antivipmyn Africa) against African vipers and elapids. Toxicon, 2008, 52, 881-888. [CrossRef] [PubMed] [Google Scholar]
  • Reid H.A., Thean P.C., Martin W.J., Specific antivenene and prednisone in viper-bite poisoning: controlled trial. Br Med J, 1963, 2, 1378-1380. [CrossRef] [PubMed] [Google Scholar]
  • Rivière G., Choumet V., Audebert F., Sabouraud A., Debray M., Scherrmann J.-M., Bon C., Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: Towards an optimization of antivenom therapy. J Pharmacol Exp Ther, 1997, 281, 1-8. [PubMed] [Google Scholar]
  • Rivière G., Choumet V., Saliou B., Debray M., Bon, C., Absorption and elimination of viper venom after antivenom administration. J Pharmacol Exp Ther, 1998, 285, 490-495. [PubMed] [Google Scholar]
  • Roux P., Yersin A., Contribution à l'étude de la diphtérie. Ann Inst Pasteur, 1888, 2, 629-49. [Google Scholar]
  • Sewall H., Experiments on the preventive inoculation of rattlesnake venom. J Physiol, London, 1887, 8, 203-210. [Google Scholar]
  • Stock R.P, Massougbodji A., Alagón A., Chippaux J.-P., Bringing antivenom to Sub-Saharan Africa. Nature Biotechnol, 2007, 25, 173-177. [CrossRef] [Google Scholar]
  • Theakston R.D., Warrell D.A., Crisis in snake antivenom supply for Africa. Lancet, 2000, 356, 2104. [CrossRef] [Google Scholar]
  • Vázquez H., Chávez-Haro A., García-Ubbelohde W., Mancilla-Nava R., Paniagua-Solís J., Alagón A., Sevcik C., Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers. Toxicon, 2005, 46, 797-805. [CrossRef] [PubMed] [Google Scholar]
  • Visser L.E., Kyei-Faried S., Belcher D.W., Geelhoed D.W., Schagen van Leeuwen J., van Roosmalen J., Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance. Trans R Soc Trop Med Hyg, 2008, 102, 445-450. [CrossRef] [PubMed] [Google Scholar]
  • Vitodegni N., Les accidents de la circulation et les traumatismes. La gestion des données. Expérience du Bénin. Conférence africaine sur la sécurité routière, 05-07 février 2007, Accra, Ghana. http://www4.worldbank.org/afr/ssatp/Open.aspx?id=747 accédé le 13 mai 2009. [Google Scholar]
  • Warrell D.A., Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product – “what”s in a name? Trans R Soc Trop Med Hyg, 2008, 102, 397-399. [Google Scholar]
  • WHO, Guidelines on Production, Control and Regulation of snake antivenom immunoglobulins, OMS, Genève, sous presse. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.